ReviewTherapeutic advances in gastroenterology2015
Treatment and management of ascites and hepatorenal syndrome: an update.
Review in Therapeutic advances in gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Chinese guidelines on the management of ascites and its related complications in cirrhosis.Hepatology international · 2019Guideline
- The interplay between lymphatic system and portal hypertension: a comprehensive review.Hepatology international · 2025Review
- Ascites complications risk factors of decompensated cirrhosis patients: logistic regression and prediction model.BMC gastroenterology · 2025Article
- Innovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis and Associated Syndromes.Life (Basel, Switzerland) · 2025Review
- From Pathophysiology to Practice: Evolving Pharmacological Therapies, Clinical Complications, and Pharmacogenetic Considerations in Portal Hypertension.Metabolites · 2025Review
- Article
- Interventional Management of Portal Hypertension in Cancer Patients.Current oncology reports · 2022Review
- COVID-19 and hepatorenal syndrome.World journal of gastroenterology · 2022Review
- Alcoholic liver disease: Current insights into cellular mechanisms.World journal of biological chemistry · 2021Review
- Anti-Malignant Ascites Effect of Total Diterpenoids fromMolecules (Basel, Switzerland) · 2021Article
- A Review for the Practicing Clinician: Hepatorenal Syndrome, a Form of Acute Kidney Injury, in Patients with Cirrhosis.Clinical and experimental gastroenterology · 2021Review
- Current approaches to the management of patients with cirrhotic ascites.World journal of gastroenterology · 2019Review
- Nutritional support in chronic liver disease and cirrhotics.World journal of hepatology · 2018Review
- High expression of type I inositol 1,4,5-trisphosphate receptor in the kidney of rats with hepatorenal syndrome.World journal of gastroenterology · 2018Article
- Management of refractory cirrhotic ascites: challenges and solutions.Hepatic medicine : evidence and research · 2018Review
- [Guidelines on the management of ascites and complications in cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017Article
- Nutritional evaluation in cirrhosis: Emphasis on the phase angle.World journal of hepatology · 2016Review
- [Hepatorenal syndrome in decompensated cirrhosis : A special form of acute renal failure].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2016Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ascites and renal dysfunction are frequent complications experienced by patients with cirrhosis of the liver. Ascites is the pathologic accumulation of fluid in the peritoneal cavity, and is one of the cardinal signs of portal hypertension. The diagnostic evaluation of ascites involves assessment of its granulocyte count and protein concentration to exclude complications such as infection or malignoma and to allow risk stratification for the development of spontaneous peritonitis. Although sodium restriction and diuretics remain the cornerstone of the management of ascites, many patients require additional therapy when they become refractory to this treatment. In this situation, the treatment of choice is repeated large-volume paracentesis. Alteration in splanchnic hemodynamics is one of the most important changes underlying the development of ascites. Further splanchnic dilation leads to changes in systemic hemodynamics, activating vasopressor agents and leading to decreased renal perfusion. Small alterations in renal function influence the prognosis, which depends on the cause of renal failure. Prerenal failure is evident in about 70% of patients, whereas in about 30% of patients the cause is hepatorenal syndrome (HRS), which is associated with a worse prognosis. Therefore, effective therapy is of great clinical importance. Recent data indicate that use of the new definition of acute kidney injury facilitates the identification and treatment of patients with renal insufficiency more rapidly than use of the current criteria for HRS. In this review article, we evaluate approaches to the management of patients with ascites and HRS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.